ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Real-world implementation of a standardized administration protocol for zolbetuximab-associated nausea and vomiting: a retrospective supportive-care cohort study.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma.Medical oncology (Northwood, London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundZolbetuximab frequently causes infusion-related nausea and vomiting, which may lead to infusion interruption in routine practice. We developed and implemented a standardized institutional protocol for zolbetuximab administration and chemotherapy-induced nausea and vomiting (CINV) management.
methodsThis single-center retrospective descriptive cohort study included all consecutive eligible patients with unresectable or recurrent, HER2-negative, CLDN18.2-positive advanced gastric, or gastroesophageal junction adenocarcinoma who received zolbetuximab-containing chemotherapy between June 2024 and December 2025. The protocol incorporated structured antiemetic prophylaxis and real-time nausea assessment using the Wong-Baker FACES® Rating Scale (FRS). FRS ≥ 3 was used as an institutional operational threshold for temporary interruption and stepwise re-initiation; it was not intended to be formally equivalent to CTCAE grade 2 nausea.
resultsSeventeen consecutive patients were included, and no eligible patients were excluded after screening. During cycle 1, the acute-phase total control (TC) rate was 70.6% (12/17; 95% CI, 44.0-89.7). TC rates during the delayed, ultra-delayed, and overall phases were 70.6%, 82.4%, and 70.6%, respectively. Complete response rates were 100.0% in the acute phase and remained above 94% across all phases. Temporary infusion interruption occurred in 4 patients (23.5%); 3 interruptions (17.6%) were attributed to nausea and 1 (5.9%) to severe epigastric pain. All planned infusions were completed. Serum albumin showed a transient decline during early cycles followed by gradual recovery.
conclusionsIn this small, non-comparative retrospective cohort, protocol-based zolbetuximab administration was feasible in routine practice, and all patients completed the planned cycle 1 infusion. Albumin findings and survival outcomes should be interpreted as exploratory and hypothesis-generating.
Indexed as
Identifiers
42477146What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.